Results from a study using misoprostol for management of incomplete abortion in Vietnamese hospitals: implications for task shifting

Nguyen Thi Nhu Ngoc, Tara Shochet, Jennifer Blum, Pham Thanh Hai, Duong Lan Dung, Tran Thanh Nhan, Beverly Winikoff, Nguyen Thi Nhu Ngoc, Tara Shochet, Jennifer Blum, Pham Thanh Hai, Duong Lan Dung, Tran Thanh Nhan, Beverly Winikoff

Abstract

Background: Complications following spontaneous or induced abortion are a major cause of maternal morbidity. To manage these complications, post-abortion care (PAC) services should be readily available and easy to access. Standard PAC treatment includes surgical interventions that are highly effective but require surgical providers and medical centers that have the necessary space and equipment. Misoprostol has been shown to be an effective alternative to surgical evacuation and can be offered by lower level clinicians. This study sought to assess whether 400 mcg sublingual misoprostol could effectively evacuate the uterus after incomplete abortion and to confirm its applicability for use at lower level settings.

Methods: All women presenting with incomplete abortion at one of three hospitals in Vietnam were enrolled. Providers were not asked to record if the abortion was spontaneous or induced. It is likely that all were spontaneous given the legal status and easy access to abortion services in Vietnam. Participants were given 400 mcg sublingual misoprostol and instructed to hold the pills under their tongue for 30 minutes and then swallow any remaining fragments. They were then asked to return one week later to confirm their clinical status. Study clinicians were instructed to confirm a complete expulsion clinically. All women were asked to complete a questionnaire regarding satisfaction with the treatment.

Results: Three hundred and two women were enrolled between September 2009 and May 2010. Almost all participants (96.3%) had successful completions using a single dose of 400 mcg misoprostol. The majority of women (87.2%) found the side effects to be tolerable or easily tolerable. Most women (84.3%) were satisfied or very satisfied with the treatment they received; only one was dissatisfied (0.3%). Nine out of ten women would select this method again and recommend it to a friend (91.0% and 90.0%, respectively).

Conclusions: This study confirms that 400 mcg sublingual misoprostol effectively evacuates the uterus for most women experiencing incomplete abortion. The high levels of satisfaction and side effect tolerability also attest to the ease of use of this method. From these data and given the international consensus around the effectiveness of misoprostol for incomplete abortion care, it seems timely that use of the drug for this indication be widely expanded both throughout Vietnam and wherever access to abortion care is limited.

Trial registration: ClinicalTrials.gov, NCT00670761.

Figures

Figure 1
Figure 1
Participant flowchart.

References

    1. World Health Organization (WHO) Unsafe abortion: Global and regional estimates of the incidence of unsafe abortion and associated mortality in 2008. 6. Geneva: WHO; 2011.
    1. Dao B, Blum J, Thieba B, Raghavan S, Ouedraego M, Lankoande J, Winikoff B. Is misoprostol a safe, effective and acceptable alternative to manual vacuum aspiration for postabortion care? Results from a randomised trial in Burkina Faso, West Africa. BJOG. 2007;114(11):1368–75. doi: 10.1111/j.1471-0528.2007.01468.x.
    1. Bique C, Ustá M, Debora B, Chong E, Westheimer E, Winikoff B. Comparison of misoprostol and manual vacuum aspiration for the treatment of incomplete abortion. Int J Gynaecol Obstet. 2007;98(3):222–6. doi: 10.1016/j.ijgo.2007.05.003.
    1. Weeks A, Alia G, Blum J, Winikoff B, Ekwaru P, Durocher J, Mirembe F. A randomized trial of misoprostol compared with manual vacuum aspiration for incomplete abortion. Obstet Gynecol. 2005;106(3):540–7. doi: 10.1097/01.AOG.0000173799.82687.dc.
    1. Diop A, Raghavan S, Rakotovao JP, Comendant R, Blumenthal PD, Winikoff B. Two routes of administration for misoprostol in the treatment of incomplete abortion: A randomized clinical trial. Contraception. 2009;79(6):456–62. doi: 10.1016/j.contraception.2008.11.016.
    1. Dabash R, Ramadan MC, Darwish E, Hassanein N, Blum J, Winikof B. A randomizes controlled trial of 400-μg sublingual misoprostol versus manual vacuum aspiration for the treatment of incomplete abortion in two Egyptian hospitals. Int J Gynaecol Obstet. 2010;111(2):131–5. doi: 10.1016/j.ijgo.2010.06.021.
    1. Shochet T, Diop A, Gaye A, Nayama M, Sall AB, Bukola F, Blandine T, Abiola OM, Dao B, Olayinka O, Winikoff B. Sublingual misoprostol versus standard surgical care for treatment of incomplete abortion in five sub-Saharan African countries. BMC Pregnancy Childbirth. 2012;12(1):127. doi: 10.1186/1471-2393-12-127.
    1. Nguyen TN, Blum J, Durocher J, Quan TT, Winikoff B. A randomized controlled study comparing 600 versus 1,200 microg oral misoprostol for medical management of incomplete abortion. Contraception. 2005;72(6):438–42. doi: 10.1016/j.contraception.2005.05.010.
    1. Neilson JP, Gyte GM, Hickey M, Vazquez JC, Dou L. Medical treatments for incomplete miscarriage (less than 24 weeks) Cochrane Database Syst Rev. 2010;20(1):CD007223.
    1. Blandine T, Ouattara AZ, Coral A, Hassane C, Clotaire H, Dao B, Lankoande J, Diop A, Blum J. Oral misoprostol as first-line care for incomplete abortion in Burkina Faso. Int J Gynaecol Obstet. 2012;119(2):166–9. doi: 10.1016/j.ijgo.2012.05.036.
    1. Fawole AO, Diop A, Adeyanju AO, Aremu OT, Winikoff B. Misoprostol as first-line treatment for incomplete abortion at a secondary-level health facility in Nigeria. Int J Gynaecol Obstet. 2012;119(2):170–3. doi: 10.1016/j.ijgo.2012.06.012.
    1. Moreau C, Trussell J, Desfreres J, Bajos N. Medical vs. surgical abortion: the importance of women's choice. Contraception. 2011;84(3):224–9. doi: 10.1016/j.contraception.2011.01.011.
    1. Ngoc N, Winikoff B, Clark S, Ellertson C, Am K, Hieu D, Elul B. Safety, Efficacy and Acceptability of Mifepristone-Misoprostol Medical Abortion in Vietnam. IntFam Plan Perspect. 1999;25(1):10–14. doi: 10.2307/2991896.
    1. Winikoff B, Sivin I, Coyaji K, Cabezas E. et al.The Acceptability of medical abortion in China, Cuba and India. Int Fam Plan Perspect. 1997;23:73–78. doi: 10.2307/2950827.
    1. World Health Organization. Safe abortion: Technical and policy guidance for health systems. 2. Geneva: WHO; 2012.
    1. World Health Organization. WHO Model List of Essential Medicines.17th List. Geneva: WHO; 2011.
    1. Venture Strategies Innovations (VSI) Postabortion care. Available at: . Accessed July 25, 2012.
    1. Priority life‒saving medicines for women for major causes of sexual and reproductive health related mortality and morbidity. WHO; 2012. . Accessed January 15, 2013.
    1. Fjerstad M. Figuring out follow-up. Mifematters PPFA/CAPS. 2006;13:2–3.
    1. American College of Obstetricians and Gynecologists. Misoprostol for postabortion care.ACOG Committee Opinion No. 427. Obstet Gynecol. 2009;113:465–8.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner